skip to main content
Idioma:
Resultados 1 2 next page
Refinado por: Nome da Publicação: Annals Of Oncology remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC
1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC
Material Type:
Artigo 		Adicionar ao Meu Espaço

1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC

Mazzaschi, G. ; Moron Dalla Tor, L. ; Balbi, M. ; Milanese, G. ; Tognazzi, D. ; Lorusso, B. ; Trentini, F. ; Di Rienzo, G. ; Verzè, M. ; Pluchino, M. ; Minari, R. ; Leo, L. ; Gnetti, L. ; Bordi, P. ; Leonetti, A. ; Ampollini, L. ; Roti, G. ; Quaini, F. ; Sverzellati, N. ; Tiseo, M.

Annals of oncology, 2022-09, Vol.33, p.S1039 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
2
1589P Chronological pattern of venous thromboembolism (VTE) occurrence impacts in survival of pancreatic ductal adenocarcinoma (PDAC)
1589P Chronological pattern of venous thromboembolism (VTE) occurrence impacts in survival of pancreatic ductal adenocarcinoma (PDAC)
Material Type:
Artigo 		Adicionar ao Meu Espaço

1589P Chronological pattern of venous thromboembolism (VTE) occurrence impacts in survival of pancreatic ductal adenocarcinoma (PDAC)

Gonzalez Caraballo, I. ; Martín Lozano, R. ; Jiménez Rodríguez, R. ; Lobato Delgado, B. ; Cañete Muñoz, M.A. ; Benavente, M. ; Palma, M. ; De Toro Carmena, M.T. ; Morón, B.I. ; Tirado Anula, V.C. ; Soto Alsar, J. ; Bringas Beranek, M. ; Gutierrez Alonso, N. ; López Jiménez, C. ; Gutiérrez Ortiz de la Tabla, A. ; Juliao Caamaño, D.S. ; Ortega Morán, L. ; Soria Fernandez, J.M. ; Martin Jimenez, M. ; Munoz Martin, A.J.

Annals of oncology, 2022-09, Vol.33, p.S1271-S1272 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
3
P-11 Venous thromboembolism in colorectal cancer patients with BRAF mutation
P-11 Venous thromboembolism in colorectal cancer patients with BRAF mutation
Material Type:
Artigo 		Adicionar ao Meu Espaço

P-11 Venous thromboembolism in colorectal cancer patients with BRAF mutation

Ortega Morán, L. ; Pesántez, D. ; Brozos Vázquez, E. ; Fernández Garay, D. ; Lobo de Mena, M. ; Ribera Fernández, P. ; Sánchez Cánovas, M. ; Salgado Fernandez, M. ; García Pérez, E. ; Iriarte Moncho, E. ; Morón García, B. ; Font, C. ; Gallardo, E. ; Pérez Altozano, J. ; Muñoz Martín, A.

Annals of oncology, 2022-06, Vol.33, p.S249-S250 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
4
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients
Material Type:
Artigo 		Adicionar ao Meu Espaço

17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients

Mazzaschi, G. ; Milanese, G. ; Moron Dalla Tor, L. ; Leo, L. ; Balbi, M. ; Trentini, F. ; Manini, M. ; Pavone, C. ; Silva, M. ; Ledda, R.E. ; Minari, R. ; Bordi, P. ; Buti, S. ; Leonetti, A. ; Roti, G. ; Quaini, F. ; Sverzellati, N. ; Tiseo, M.

Annals of oncology, 2021-12, Vol.32, p.S1380-S1381 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
5
72PCemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2)
72PCemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2)
Material Type:
Artigo 		Adicionar ao Meu Espaço

72PCemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2)

Moreno, V ; Gil-Martin, M ; Johnson, M L ; Aljumaily, R ; Lopez Criado, P ; Northfelt, D W ; Crittenden, M ; Jabbour, S ; Rosen, L ; Garrido, P ; Hervás Morón, A ; Rietschel, P ; Mohan, K K ; Li, J ; Stankevich, E ; Feng, M ; Lowy, I ; Fury, M G

Annals of oncology, 2018-12, Vol.29 (suppl_10) [Periódico revisado por pares]

Oxford University Press

Texto completo disponível

Citações Citado por
6
Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2)
Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2)

Moreno, V. ; Gil-Martin, M. ; Johnson, M.L. ; Aljumaily, R. ; Lopez Criado, P. ; Northfelt, D.W. ; Crittenden, M. ; Jabbour, S. ; Rosen, L. ; Garrido, P. ; Hervás Morón, A. ; Rietschel, P. ; Mohan, K.K. ; Li, J. ; Stankevich, E. ; Feng, M. ; Lowy, I. ; Fury, M.G.

Annals of oncology, 2018-12, Vol.29, p.x26-x26 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
7
1409PAssociation of efficacy and immune-related adverse events (irAEs) in patients with NSCLC receiving immune-checkpoint inhibitors (ICIs)
1409PAssociation of efficacy and immune-related adverse events (irAEs) in patients with NSCLC receiving immune-checkpoint inhibitors (ICIs)
Material Type:
Artigo 		Adicionar ao Meu Espaço

1409PAssociation of efficacy and immune-related adverse events (irAEs) in patients with NSCLC receiving immune-checkpoint inhibitors (ICIs)

Riudavets Melia, M ; Gabriela Sullivan, I ; Barba Joaquín, A ; Anguera Palacios, G ; del Carpio, L P ; Molto Valiente, C ; Camacho Arellano, S D ; Moron Asensio, S ; Gomila Pons, P ; Andres Granyó, M ; Castillo Villegas, D ; Facundo Molas, C ; Garcia Planella, E ; González Blanco, C ; Barnadas Molins, A ; Gich Saladich, I ; Majem Tarruella, M

Annals of oncology, 2018-10, Vol.29 (suppl_8) [Periódico revisado por pares]

Oxford University Press

Texto completo disponível

Citações Citado por
8
388PImpaired survival in resected glioblastoma multiforme patients treated with early chemoradiation
388PImpaired survival in resected glioblastoma multiforme patients treated with early chemoradiation
Material Type:
Artigo 		Adicionar ao Meu Espaço

388PImpaired survival in resected glioblastoma multiforme patients treated with early chemoradiation

del Carpio, L P ; Gomila, P ; Camacho, S D ; Moron, S ; Riudavets, M ; Molto, C ; Bujosa, A ; Borrell, M ; Teres, R ; Martin, B ; Gallardo, P ; Acosta, E ; Tilea, L ; Soto, A ; De Quintana, C ; Craven-Bartle, J ; Gallardo, A ; Gomez, B ; Bonilla, S ; Gallego, O

Annals of oncology, 2018-10, Vol.29 (suppl_8) [Periódico revisado por pares]

Oxford University Press

Texto completo disponível

Citações Citado por
9
1162PCemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2)
1162PCemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2)
Material Type:
Artigo 		Adicionar ao Meu Espaço

1162PCemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2)

Moreno, V ; Gil-Martin, M ; Johnson, M ; Aljumaily, R ; Lopez Criado, P ; Northfelt, D W ; Crittenden, M ; Jabbour, S ; Rosen, L ; Garrido Lopez, P ; Hervás Morón, A ; Rietschel, P ; Mohan, K K ; Li, J ; Stankevich, E ; Rowlands, T ; Feng, M ; Lowy, I ; Fury, M G

Annals of oncology, 2018-10, Vol.29 (suppl_8) [Periódico revisado por pares]

Oxford University Press

Texto completo disponível

Citações Citado por
10
Association of efficacy and immune-related adverse events (irAEs) in patients with NSCLC receiving immune-checkpoint inhibitors (ICIs)
Association of efficacy and immune-related adverse events (irAEs) in patients with NSCLC receiving immune-checkpoint inhibitors (ICIs)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Association of efficacy and immune-related adverse events (irAEs) in patients with NSCLC receiving immune-checkpoint inhibitors (ICIs)

Riudavets Melia, M. ; Gabriela Sullivan, I. ; Barba Joaquín, A. ; Anguera Palacios, G. ; del Carpio, L.P. ; Molto Valiente, C. ; Camacho Arellano, S.D. ; Moron Asensio, S. ; Gomila Pons, P. ; Andres Granyó, M. ; Castillo Villegas, D. ; Facundo Molas, C. ; Garcia Planella, E. ; González Blanco, C. ; Barnadas Molins, A. ; Gich Saladich, I. ; Majem Tarruella, M.

Annals of oncology, 2018-10, Vol.29, p.viii509-viii509 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
Resultados 1 2 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Refinar Meus Resultados

Data de Publicação 

De até
Refinar

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.